Department of Psychology, Faculty of Medicine, University of Helsinki
Helsinki, Uusimaa, 00200, Finland
Location status: Recruiting
Location contact
Manon Chédeville, Doctoral Researcher
CONTACT
Professor Horstmann
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07112521
The goal of this intervention is to investigate whether transcranial Direct Current Stimulation (tDCS) can alleviate Cancer-Related Cognitive Impairment (CRCI) in breast cancer survivors, as measured by changes in brain structures and cognitive performance. To assess the efficacy of tDCS, the investigators will compare outcomes between participants receiving active stimulation and those receiving sham stimulation (a placebo condition where participants believe they are receiving stimulation, but are not).
Participants will:
* Undergo a baseline MRI session * Receive either active or sham tDCS for six weeks * Undergo a follow-up MRI session * Complete cognitive tests and respond to psychosocial questionnaires before, during, and after the tDCS intervention
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Helsinki, Uusimaa, 00200, Finland
Location status: Recruiting
Manon Chédeville, Doctoral Researcher
CONTACT
Professor Horstmann
PRINCIPAL_INVESTIGATOR
Cancer-Related Cognitive Impairment (CRCI) is common among breast cancer (BC) survivors, manifesting as deficits in memory, attention, and processing speed, further affecting their quality of life. CRCI is likely multifactorial, influenced by demographic and genetic factors, neuroinflammation, and neuroplasticity changes. On the one hand, obesity is a known risk factor for BC and a poorer prognosis. On the other hand, it is linked to neuroinflammation and structural brain changes that contribute to cognitive impairment. However, its role in exacerbating CRCI remains unclear. Understanding this relationship is crucial for optimizing cognitive rehabilitation strategies. Transcranial Direct Current Stimulation (tDCS) is a promising neuromodulation technique that enhances neuroplasticity, and its potential for home-based application could improve treatment feasibility. This study aims to (1) evaluate the effectiveness of home-based tDCS in improving cognitive function in BC survivors and (2) examine obesity as a potential moderator of treatment outcomes. The investigators will conduct a double-blind, sham-controlled tDCS intervention over six weeks, collecting cognitive assessments and dietary data before, during, and after the intervention. MRI scans will be acquired pre- and post-intervention to assess structural and functional changes in cognition-related regions.
Participants will complete five phases over seventeen weeks: baseline, intervention (acute schedule), intervention (continuing schedule), short-term follow-up, and long-term follow-up:
Cognitive assessment includes three cognitive tests representing three domains known to be impaired following breast cancer (Small et al., 2019):
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.
Time frame: From baseline to the end of the intervention at 6 weeks
Performance in the Matching Cards task under active tDCS compared to sham: the mean number of correct trials.
Time frame: From baseline to the end of the intervention at 6 weeks
Performance in the dot memory task under active tDCS compared to sham: the mean Euclidean distance score.
The mean Euclidean distance score reflects the distance between the original red dot locations and the recalled locations.
Time frame: From baseline to the end of the intervention at 6 weeks
Performance in Symbol Search task under active tDCS compared to sham: prompt-level median response latency for correct trials.
Time frame: From baseline to 3 weeks after the end of the intervention
Performance in the Matching Cards task under active tDCS compared to sham: the mean number of correct trials.
Time frame: From baseline to 3 weeks after the end of the intervention
Performance in the dot memory task under active tDCS compared to sham: the mean Euclidean distance score.
The mean Euclidean distance score reflects the distance between the original red dot locations and the recalled locations.
Time frame: From baseline to 3 weeks after the end of the intervention
Performance in Symbol Search task under active tDCS compared to sham: prompt-level median response latency for correct trials.
Time frame: From baseline to 9 weeks after the end of the intervention
Performance in the Matching Cards task under active tDCS compared to sham: the mean number of correct trials.
Time frame: From baseline to 9 weeks after the end of the intervention
Performance in the dot memory task under active tDCS compared to sham: the mean Euclidean distance score.
The mean Euclidean distance score reflects the distance between the original red dot locations and the recalled locations.
Time frame: From baseline to 9 weeks after the end of the intervention
Performance in Symbol Search task under active tDCS compared to sham: prompt-level median response latency for correct trials.
Time frame: From baseline to 9 weeks after the end of the intervention
Volume of gray matter under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
Thickness of gray matter under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
Neurite density index under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
Orientation dispersion index under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
Free-water fraction under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
ROI-to-ROI functional connectivity as measured by resting-state fMRI under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
Seed-based functional connectivity as measured by resting-state fMRI under active tDCS compared to sham.
Time frame: From baseline to week 1-3-5 during the the intervention
Performance in the Matching Cards task under active tDCS compared to sham: the mean number of correct trials from each prompted assessment.
Time frame: From baseline to week 1-3-5 during the the intervention
Performance in the dot memory task under active tDCS compared to sham: the mean Euclidean distance score from each prompted assessment.
Time frame: From baseline to week 1-3-5 during the the intervention
Performance in Symbol Search task under active tDCS compared to sham: the mean of the prompt-level median response latency for correct trials.
Time frame: From baseline to the end of treatment at 6 weeks
HADS score under active tDCS compared to sham.
Time frame: From baseline to 3 weeks after the end of the intervention
HADS score under active tDCS compared to sham.
Time frame: From baseline to 9 weeks after the end of the intervention
HADS score under active tDCS compared to sham.
Contact information is provided by the study sponsor or research team.
University of Helsinki
Other
Evaluating the Efficacy of Home-Based tDCS for Cancer-Related Cognitive Impairment and Its Moderation by Obesity: A Double-Blind Randomized Controlled Trial.
Acronym: LUMINA-brain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07591857
Breast Cancer Survivor, Cancer Related Cognitive Impairment
Jerusalem, Israel
View Trial DetailsNCT07312786
Breast Cancer Survivor, Colorectal Cancer Survivors
Saint John, New Brunswick, Canada
View Trial DetailsNCT06938555
Adherence Interventions, Behavior
Phoenix, Arizona, United States
View Trial DetailsNCT06728579
Arthralgia, Breast Cancer Survivor
San Diego, California, United States
View Trial Details